Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | VHL | P40337 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL9938634 | 0.88 | KMT2A (0.53) | KMT2AMEN1ADAMTS4MMP13SMN1; SMN2 | |
| Cadaverine Tartrate SCHEMBL9937385 | 0.88 | KMT2A (0.53) | KMT2AMEN1ADAMTS4MMP13SMN1; SMN2 | |
| Cadaverine Tartrate SCHEMBL3633165 | 0.86 | ADAMTS4 (0.48) | KMT2AMEN1ADAMTS4MMP13SMN1; SMN2 | |
| Cadaverine Tartrate SCHEMBL9936743 | 0.85 | ADAMTS4 (0.53) | KMT2AMEN1ADAMTS4MMP13SMN1; SMN2 | |
| SCHEMBL171709 | 0.83 | KMT2A (0.66) | KMT2AMEN1SMN1; SMN2ALDH1A1LMNA | |
| Cadaverine Tartrate SCHEMBL3634786 | 0.83 | PPARA (0.51) | KMT2AADAMTS4MMP13HDAC1HDAC3 | |
| SCHEMBL5801663 | 0.79 | KMT2A (0.65) | KMT2AMEN1ADAMTS4MMP13SMN1; SMN2 | |
| SCHEMBL12133623 | 0.76 | KMT2A (0.76) | KMT2AMEN1SMN1; SMN2VHLALDH1A1 | |
| Toluene SCHEMBL29122543 | 0.75 | SMN1; SMN2 (0.68) | KMT2AMEN1SMN1; SMN2ALDH1A1HDAC1 | |
| SCHEMBL5437522 | 0.75 | KDM4E (0.59) | KMT2AADAMTS4MMP13SMN1; SMN2VHL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651403-A2 | USE OF LP-PLA2 INHIBITORS IN THE TREATMENT AND PREVENTION OF EYE DISEASES | Glaxo Group Limited (GB) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080497-A2 | METHODS OF TREATMENT AND PREVENTION OF EYE DISEASES | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | WO | disclosed |